• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    Pfizer, BioNTech Adapt COVID Vax Against Omicron

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Vector Partners Limited

    IDT Biologika

    Biosynth Carbosynth

    Baxter BioPharma Solutions

    Kyongbo Pharmaceutical
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Vector Partners Limited

    IDT Biologika

    Biosynth Carbosynth

    Baxter BioPharma Solutions

    Kyongbo Pharmaceutical
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

    The proven promise and huge potential of using AI and ML to accelerate drug discovery.

    Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI
    Related CONTENT
    • Probing the Limits of Pharma’s Future
    • Better Drug Manufacturing Strategies: Custom APIs
    • Tufts CSDD Names Ken Getz New Deputy Director
    • Four Pitfalls to Avoid When Packaging Injectable Drug Products
    • Permira Funds to Acquire Cambrex in $2.4B Transaction
    Lucas Glass, Gary Shorter, and Rajneesh Patil, IQVIA10.21.19
    Artificial intelligence and machine learning tools are transforming how clinical development occurs by delivering significant time and cost efficiencies while providing better and faster insights to inform decision-making. Advances in analytics technology coupled with the availability and integration of vast amounts of healthcare data have already helped automate processes and improve data quality across dozens of clinical development efforts.

    As these tools evolve, new opportunities will continue to emerge that drive further benefits to the clinical research landscape. Applications of AI and ML in healthcare are expected to grow to nearly $8 billion by 2022, up from $667.1 million in 2016, and almost half of global life science professionals say they are either using or interested in using AI in their research.[1]

    Despite this growth, the industry continues to struggle with what these technologies are and how they work. And there is uncertainty on how to surmount the challenges required to leverage AI and ML.

    When sponsors collaborate with partners that have the necessary technical and pharmaceutical expertise, they can achieve significant time and cost savings while reducing risks and improving the quality of their research. Here are five proven areas where AI and ML can directly impact operational efficiencies:

    1. Study design
    Poor study design has a catastrophic impact on the cost, efficiency and success potential of clinical trials. Leveraging vast healthcare data sets, AI, ML and natural language processing tools can be used to assess and select optimal primary and secondary endpoints during study design to ensure the most relevant protocols are defined for regulators, payers and patients. This helps to optimize the study design by informing ideal strategies for host countries and sites, enrollment models, patient recruitment and start-up plans.

    Better study design leads to more predictable results, reduced cycle time for protocol development, fewer protocol amendments and higher efficiencies throughout a study. It also results in improved recruitment rates and fewer non-enrolling sites. These improvements facilitate realistic and accurate planning and increase chances of success.

    2. Site identification and patient recruitment
    Identifying trial sites that have access to enough patients who meet inclusion/exclusion criteria is an ongoing challenge. As studies target more specific populations, recruiting goals become even harder to achieve, which drives costs up, increases timelines and raises the risk of failure. According to Tufts Center for the Study of Drug Development, nearly half of all sites miss enrollment targets.

    AI and ML can mitigate these risks by identifying and suggesting the sites with the highest recruitment potential and suggesting appropriate recruitment strategies. This involves mapping patient populations and proactively targeting sites with high predicted potential to deliver the most patients — before a single site is opened — and identifying the best avenues to recruit them. This means sponsors can open fewer sites, accelerate recruiting and reduce the risk of under-enrollment.

    3. Pharmacovigilance
    To ensure drug safety, massive amounts of structured and unstructured data must be integrated and reviewed. PV units that seek to harness the power of this data find that AI and ML technologies address many of the challenges they face by providing new levels of insight and predictive analytics. These tools can automate manual processing tasks and translate and digitize case safety reporting and adverse drug reaction documents. They can also monitor digital conversations on social media and other platforms to ensure that adverse events are promptly identified.

    Natural language processing, Optical character recognition, and deep neural networks are being used to analyze and format structured and unstructured data for faster and more efficient safety reviews.

    The insights derived from using AI for PV tasks lead to faster assessment of subject, site and study risks and overall study performance by domain experts. This allows project leads to increase efficiencies as well as patient safety.

    4. Clinical monitoring
    Tremendous manual effort is spent analyzing site risks and generating “action items” to mitigate those risks. AL and ML concepts can alleviate these pressures by assessing the risk environment and delivering predictive analytics to generate more effective clinical monitoring insights.

    Advanced analytics provide composite site rankings for holistic risk assessments, allowing for more specific identification of risks and removal of false positives. Using the composite evaluation of site risks across the study quickly shows high-risk sites, key risk indicators and site risk rank. Evaluations can also be used to proactively identify which sites are more likely to have recruitment and performance issues, or which patients are at higher risk for potential AEs. These insights facilitate faster action and avoid potential problems.

    5. Patient care
    Disease detection algorithms are now being designed to leverage medical information, such as symptoms and procedures that typically precede a diagnosis, to identify patients who are very likely to develop diseases. This allows for proactive care, as well as new recruiting insights for prodromal or early-stage disease studies and those that require treatment-naive patients.

    One area where this type of model is having a profound impact is Alzheimer’s disease research. Due to the exponential effects of a delayed AD diagnosis, much clinical research activity in AD is focused on the prodromal stage. Yet, traditional screenings for prodromal AD patients deliver only a 20 percent precision rate.

    AI and ML: Augmenting the Future of Clinical Development
    The clinical development landscape is changing quickly, and sponsors need to have the best insights to make the right decisions to increase predictability, reduce time to market and improve efficiencies. By using these methods in clinical development, we can introduce change to prove — and improve — how AI-derived insights can be applied to many aspects of development.

    These technologies aren’t going to replace human expertise. But they are going to accelerate the ability to analyze the data and take meaningful action in response to create a safer, more streamlined research environment. As the volume and complexity of clinical data continue to increase and more real-world evidence is introduced, AI applications have great potential value for the clinical trial process and the pharmaceutical drug discovery industry.

    Talent, Technology and Expertise
    These technologies hold huge promise for clinical development, but that promise can only be achieved when organizations have the tools, talent and partners to leverage these technologies in relevant ways. To achieve the full potential of AI and ML in clinical development, pharma companies need partners who can provide:

    ·      Deep pharmaceutical knowledge and domain expertise. This expertise should include in-depth understanding of healthcare data for insightful analyses, understanding of global regulatory environments, payer expectations, physician and patient behavior and therapeutic knowledge.
    ·      State-of-the-science AI and ML technologies. The solution should be capable of mining multiple data sets with speed and scale to identify high-level global and regional trends, as well as detailed physician- and patient-level insights while applying rigor through the GxP Software Development Life Cycle approach to produce top quality models.

    ·      Data analytics and machine learning experts. The customer team should include technical experts who are skilled in crafting machine learning algorithms relevant to the clinical development process.

    ·      Access to vast healthcare data sets. Machine learning algorithms are only as good as the data they can access. The most effective platforms will provide access to multiple global healthcare databases, including prescription data, EMRs, pharma sales data and patient and disease trend data that are updated regularly.

    ·      The ability to integrate these disparate data sets. Many healthcare data sets are unstructured or inconsistent in form and formatting, making them difficult to analyze. A good partner will have strategies in place to clean the data, so the algorithms can interpret results and translate them into actionable insights that drive better results.

    As the life sciences industry continues to evolve, more sophisticated analytics capabilities are required to advance the understanding of human health through better, more insightful decisions. Integrating human science with breakthroughs in data science and technology provides more relevancy and precision to decision-makers. It can transform how patients are diagnosed and treated, with minimal errors. It can help identify patients — faster and maybe even before they are patients.

    The proven promise and huge potential of using AI and ML to accelerate drug discovery while cutting costs and risks is a tremendous catalyst for innovation. By continuing to leverage data, intelligence, analytics and domain expertise, there is an enormous opportunity for the industry to fundamentally transform the clinical development landscape in ways that will greatly benefit patients, sponsors, payers and physicians alike.


    [1] Source: Accenture, “Artificial Intelligence: Healthcare’s New Nervous System,” https://www.accenture.com/au-en/insight-artificial-intelligence-healthcare



     
    Lucas Glass is the Global Head of IQVIA’s Analytics Center of Excellence; responsible for researching, developing and operationalizing machine learning and data science solutions in the R&D business.






     
    Gary Shorter, Head of Artificial Intelligence, Research & Development Solutions, IQVIA. Gary Shorter holds an MSc and has served as global biostatistics lead for multiple compounds in clinical trials.







     
    Rajneesh Patil, Head of Process Design & Analytics, Centralized Monitoring Services, IQVIA. Rajneesh Patil’s expertise spans process design, project portfolio management, risk-based monitoring and advanced analytics for clinical trial applications.
    Related Searches
    • discovery
    • study
    • pharmacovigilance
    • Biostatistics
    Suggested For You
    Probing the Limits of Pharma’s Future Probing the Limits of Pharma’s Future
    Better Drug Manufacturing Strategies: Custom APIs Better Drug Manufacturing Strategies: Custom APIs
    Tufts CSDD Names Ken Getz New Deputy Director Tufts CSDD Names Ken Getz New Deputy Director
    Four Pitfalls to Avoid When Packaging Injectable Drug Products Four Pitfalls to Avoid When Packaging Injectable Drug Products
    Permira Funds to Acquire Cambrex in $2.4B Transaction Permira Funds to Acquire Cambrex in $2.4B Transaction
    Pressure BioSciences Inks Contract Services Deal Pressure BioSciences Inks Contract Services Deal
    Artificial Intelligence and Machine Learning in Healthcare Artificial Intelligence and Machine Learning in Healthcare
    Pacira Appoints Max Reinhardt as President Pacira Appoints Max Reinhardt as President
    LAST CHANCE: Participate in Tufts LAST CHANCE: Participate in Tufts' Study on the Vendor Qualification Process
    The Headhunter’s Call The Headhunter’s Call
    Risk-Based Monitoring Risk-Based Monitoring
    CROs May Get a Regulatory Boost CROs May Get a Regulatory Boost
    Cryoport, CalAmp Enter Strategic Collaboration  Cryoport, CalAmp Enter Strategic Collaboration
    Tufts CSDD Study on the Vendor Qualification Process Tufts CSDD Study on the Vendor Qualification Process
    The Pharma Supply Chain The Pharma Supply Chain

    Related Content

    • Information Technology
      Probing the Limits of Pharma’s Future

      Probing the Limits of Pharma’s Future

      A retrospective on the past 20 years and a prospective on where the future will take us.
      Ben Locwin, Contributing Writer 10.15.19

    • APIs
      Better Drug Manufacturing Strategies: Custom APIs

      Better Drug Manufacturing Strategies: Custom APIs

      Today’s biopharma companies are turning to their contractors for long-term collaboration and much higher levels of support.
      Tom Wilson, VP, Global Contract Manufacturing Leader, Pfizer CentreOne 10.15.19

    • Breaking News | Industry News | Promotions & Moves
      Tufts CSDD Names Ken Getz New Deputy Director

      Tufts CSDD Names Ken Getz New Deputy Director

      Mr. Getz also promoted to the rank of Research Professor by Tufts University
      10.02.19


    • Fill/Finish | Injectables
      Four Pitfalls to Avoid When Packaging Injectable Drug Products

      Four Pitfalls to Avoid When Packaging Injectable Drug Products

      Addressing legacy systems, lack of innovation adoption, and special challenges of New Molecular Entities
      Fran DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services, Inc. 09.04.19

    • Analytical Services | cGMP Manufacture | Clinical Trial Materials | Drug Development | Industry News
      Permira Funds to Acquire Cambrex in $2.4B Transaction

      Permira Funds to Acquire Cambrex in $2.4B Transaction

      To back Cambrex in its next phase of growth
      08.07.19

      Loading, Please Wait..
      Trending
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • 17th Annual Contracting & Outsourcing Conference Photos
      • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
      • LabVantage Solutions Adds Mixed Reality Technology to Its Advanced LIMS Platform
      • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
      Breaking News
      • Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • CoreRx Expands Capabilities
      • Qosina Strengthens Aseptic Capabilities
      • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Japanese Mushroom Extract Appears Helpful in HPV Infections
      Fi & Hi Europe Returns with Over 20,000 Global Attendees Expected
      United Plant Savers Launches First Film Festival
      Coatings World

      Latest Breaking News From Coatings World

      H.M. Royal Becomes Exclusive OCSiAl Distributor
      American Colors to Expand Sandusky, Ohio Facility
      Vaughn O’Dea Named Director of Epoxytec
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Cepheid, BioGX Partner to Create GeneXpert Monkeypox Test
      Siemens' Varian Gains FDA IDE Nod for FAST-02 Trial
      Acutus Medical Launches AcQCross Line Extension
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      Pfizer, BioNTech Adapt COVID Vax Against Omicron
      CoreRx Expands Capabilities
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Top 5 Beauty Tech Trends at Perfect Corp.'s Global Forum
      John Frieda Supports the LGBTQIA+ Community
      Athena Club Launches in Canada
      Happi

      Latest Breaking News From Happi

      Past Henkel Exec Christian Chopra Named President of Scotch Porter
      Color Street Celebrates Foster, Adoption Awareness with Limited-Edition Print
      CIR Panel Conducts 161st Meeting Regarding Safety Assessments for Cosmetic Ingredients
      Ink World

      Latest Breaking News From Ink World

      Dr. Tammo Boinowitz to Join Management Board of ALTANA AG
      Flint Offset Packaging Solutions Announces Price Increases for Sheetfed Inks
      Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Harveer Sahni recognized with Global Achievement Award
      Color-Logic partners with Taktiful 
      ALTANA announces Management Board change
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Fibertex Personal Care Awarded EcoVadis Awards for Sustainability
      Yanpai Orders Batt Forming Equipment for Needlepunch Line
      Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Researchers Discover Novel Patching Material for Bone Defects
      Boston Centerless Opens Second Manufacturing Plant in Indiana
      Researchers Develop Patient-Specific 3D-Printed Smart Metamaterial Implants
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Identiv-Powered CVS Spoken Rx Wins NFC Forum 2022 Innovation Award
      LG Display Announces Winners of This Year’s OLEDs GO! Competition
      Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login